Participants should not have received any other investigational agents nor have participated in an investigational trial within the past  weeks
Patients must not have received radiation therapy, non-cytotoxic agents or investigational agents or systemic corticosteroids within  days prior to registration
Subject has received other investigational therapy within the last  days.
Patients may not be receiving or have received any other investigational agents during/or within  month prior
Patients may not have received any other investigational agents within the last  days at the time of treatment start
Patients who are receiving any other investigational or chemotherapeutic agents will be excluded; please contact the study principal investigator (PI) if a patient has received an investigational or chemotherapeutic agent in the past
Patients may not be receiving any other investigational agents; (i.e. -day washout period from prior investigational drug is required)
Patients who are receiving any other investigational agents, or have received an investigational agent within the past  days
Patients may not be receiving any other investigational agents, or have received investigational agents within  weeks of beginning treatment
Patients may not be receiving (or received prior to enrollment) any other investigational agents for metastatic disease.
Patients who are receiving any other investigational agents. A minimum washout period of  days is required prior to the initiation of on study treatment.
Patients who have received any other investigational agents within the past  days prior to cycle  day 
Receiving any other investigational agents, or has received an investigational agent within the last  days
Major surgery (including breast surgery) within <  days of starting treatment or received chemotherapy, investigational agents, or other cancer therapy <  days prior to the initiation of investigational products (except adjuvant endocrine therapy)
Patients receiving any other investigational agents; any prior investigational agents must be stopped at least  days ( week washout) prior to registration
Patients should not have received any other investigational agents within the past  weeks
Treatment with other investigational agents within  days of day 
Patients receiving any other investigational agents or whom have received recent treatment for colorectal cancer (radiation within the previous two weeks, chemotherapy or investigational therapy within the previous four weeks)
Patients who are receiving any other investigational agents, or have received an investigational agent within the past  days
Patients receiving any other investigational chemotherapeutic agents within  days prior to the first dose of trial treatment
JUST PRIOR TO FIRST VACCINATION (WITHIN  DAYS): patients may not be receiving any other investigational agents
Subjects must not have received any investigational agents within  days of study entry
Subjects may have received any other investigational agents or chemotherapy as long as they are eligible for SABR and surgery
Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past  weeks
Past history of other investigational agents
Patients must not have received other investigational agents within  days of initiation of the conditioning regimen
Patients must not have received any investigational agents within  days of study entry
Must not be receiving any other investigational agents within  days of first dose of azacitidine (day )
Simultaneous primary invasive cancers or patients currently receiving any other investigational agents at time of study enrollment. Patients may have received investigational agents in the past. No washout time period is required.
Subject has received other investigational agents or devices within  days prior to first dose of study treatment.
Participants may not have received any other investigational agents in the previous  months
Patients who have received any other investigational agents within the preceding  weeks
Patients who are receiving any other investigational agents require a  week washout period; patients who have received cellular or gene therapy at any time are not eligible
Treatment with other investigational agents within  days of day 
Patients are not eligible who have received systemic chemotherapy or investigational agents =<  days prior to registration
Subjects must not have received any investigational agents within  days of study entry
Patients may not be receiving or have received any other  investigational agents during or within  month prior to treatment with NFV
Patients who have received any other investigational agents within the last  weeks
Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =<  weeks prior to registration
PHASE II: Patients must NOT be receiving any other investigational agents concurrently and must not have received any other investigational agents =<  weeks prior to randomization
Major surgery within < days of starting treatment or received chemotherapy, investigational agents, or other cancer therapy, except hormonal therapy (eg, tamoxifen, aromatase inhibitors), < days prior to the initiation of investigational products
Received other investigational agents within  days prior to the start of the conditioning regimen
Patients may not have received any other investigational agents within  weeks of study entry
Subjects who are receiving or have received any other investigational agents within  days prior to day  of treatment in this study
Received no other investigational therapy within the past  days
Participants may not be receiving any other investigational agents nor have participated in an investigational trial within the past  weeks
Patients receiving any other investigational agents within  days prior to the first dose of trial treatment
Participants should not have received any other investigational agents nor have participated in an investigational trial within the past  weeks
Subjects who have received investigational agents within  days of the first day of study drug.
Patients who are receiving any other investigational agents or who have received pomalidomide in the past
Subjects who are receiving any other investigational agents or who have received an investigational agent within  days prior to enrollment (does not apply to participation in survival follow up), or who have previous exposure to vandetanib
Patients may not be receiving or have received any other investigational agents during/or within  month prior to treatment with oregovomab or nelfinavir
No patients receiving other investigational therapy for the past  days before dosing.
Patient must not have received any other investigational agents within  days prior to study enrollment
Patients may not be receiving any other investigational agents; any prior investigational products must be stopped at least  days (-week washout) prior to registration
Treatment with other investigational agents within  days of day 
Patients may not be receiving any other investigational agents nor have received any investigational drug  days prior to enrollment
Patients must not have received any other investigational agents within  days prior to vaccination.
Patient must not have received treatment with other investigational agents within the last  weeks
Subjects who have received investigational agents must wait at least  weeks
Received any other investigational therapy within  days of Day ; or
Patients who are receiving any other investigational agents; if the patient received a previous investigational or other agent or treatment, a washout period of  weeks is required
Subjects who have received any other investigational agents within  days of first lithium dose
Has the subject received any investigational treatment within the past  days?
Patients may not be receiving any other investigational agents; a minimum  week washout period is required
Patients who are receiving or have received any other investigational agents within  days of study day , or who have previously received MK- at any time
Subjects who are receiving any other investigational agents or have received another investigational drug in the last  days
Patients must not have received any investigational agents within  days prior to commencing study treatment
Participants may not have received any other investigational agents in the previous  months
Patients may not be receiving any other investigational agents; any prior investigational therapeutic products must be stopped at least  days ( week washout) prior to treatment start
Have received other investigational agents within the past  months (preceding the time of registration)
Patients who are receiving any other investigational agents (in the past  days) or herbal medication (within  day)
Patients who are receiving any other investigational agents (in the past  days) or herbal medications (within  day)
Patients who are receiving any other investigational agents (in the past  days) or herbal medications (within  days)